Amgen shares undervalued, says Cowen Cowen believes Amgen shares remain undervalued following Q4 results. The firm is at the high end of consensus earnings and does not include any pipeline contributions. Cowen advises investors to buy shares ahead of dividend declarations as they should support closure of the valuation gap with other pharmaceutical companies. Shares are Outperform rated.
News For AMGN From The Last 14 Days
Check below for free stories on AMGN the last two weeks.